Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, +6

PubMed

ImmunologyImmunoeditingPharmacotherapyMetronomic ChemotherapyImmunotherapy +14

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer

Jianfeng Lü, Steve Eppler, J WOLF, +4

Clinical Pharmacology & Therapeutics

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Jie Ling, Kim A. Johnson, Zhuang Miao, +5

Drug Metabolism and Disposition

Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.

Emilio Bajetta, Michele Del Vecchio, Roberta Mortarini, +7

PubMed

ImmunologyPharmacotherapyIl-12 LevelsDermatologyMetronomic Chemotherapy +16

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Ragy R. Girgis, Mark Slifstein, Deepak Cyril D’Souza, +13

Psychopharmacology

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

Ashok Rakhit, Michael Pantze, Scott Fettner, +5

European Journal of Clinical Pharmacology

Pharmacokinetic ModelingCyp3a4 InhibitionErlotinib PharmacokineticsMedicineVivo Metabolic Inhibition +6

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

Johanneke E.A. Portielje, Wim H.J. Kruit, Martin Schüler, +8

PubMed

UrologyGenitourinary CancerMedicineImmunologyClinical Trials +13

Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma

Robert J. Motzer, Ashok Rakhit, John A. Thompson, +6

Journal of Interferon & Cytokine Research

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Paul Frohna, Jianfeng Lu, Steve Eppler, +6

The Journal of Clinical Pharmacology

Oral BioavailabilityHealthy SubjectsPharmacological StudyMedicineReceptor Tyrosine Kinase +12

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

Robert J. Motzer, Ashok Rakhit, Michelle S. Ginsberg, +5

Journal of Clinical Oncology